Skip to main content

necitumumab

Generic: necitumumab·Brand: Portrazza

necitumumab: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.

necitumumab evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect necitumumab to LLY; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could necitumumab → LLY affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (1)
CompanyDated record stage
ELI LILLY & Co (LLY)
Reported 2015-11-24 · Current development: unknownSource
Approved
Clinical Trial Registry Records (1)

UCLA L-08: A Phase Ib/II Study of Combined HER Inhibition Adding Necitumumab and Trastuzumab to Osimertinib in Patients With Refractory EGFR-Mutated Lung Cancer

NCT04285671Registry updated 2026-07-17·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Identification of the recommended phase II dose (R2PD) regimen for combination osimertinib, necitumumab, trastuzumab (ONT) therapy (Phase Ib)

Interventionalopen30 enrolledStarted 2021-01Completion 2027-121 site · United StatesJonsson Comprehensive Cancer Center
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. ( 1.1 ) Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. ( 1.2 , 5.6 , 14.2 ) 1.1 Squamous Non-Small Cell Lung Cancer (NSCLC) PORTRAZZA™ is indicated, in combination with gemcitabine and cisplatin, for fir(LLY)FDA ↗
BLA125547Type 1 - New Molecular EntityStandardSubcutaneousInjectable

Frequently asked questions

Which companies have sourced relationships with necitumumab?

necitumumab has dated SEC/FDA relationship records for ELI LILLY & Co.

How many clinical trials involve necitumumab?

BioSniper tracks 1 clinical trial involving necitumumab.

What is necitumumab's latest FDA decision?

The most recent tracked FDA decision for necitumumab is Approval for 1 INDICATIONS AND USAGE PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. ( 1.1 ) Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. ( 1.2 , 5.6 , 14.2 ) 1.1 Squamous Non-Small Cell Lung Cancer (NSCLC) PORTRAZZA™ is indicated, in combination with gemcitabine and cisplatin, for fir, dated November 24, 2015.